Stock Track | Capricor Therapeutics Plunges 8.21% in After-Hours Trading as Investors Take Profits Post-Surge

Stock Track

Dec 04

Capricor Therapeutics (CAPR) saw its shares drop 8.21% in after-hours trading on Wednesday, following a dramatic intraday surge fueled by positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.

The stock had skyrocketed earlier in the day, with gains of up to 399%, after the company announced that its HOPE-3 study met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients. The after-hours decline is attributed to profit-taking by investors who capitalized on the day's substantial gains, a common occurrence following such sharp rallies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1198590499"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1198590499\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1198590499?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 09:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198590499","market":"us","top_or_hot":-1,"title":"Stock Track | Capricor Therapeutics Plunges 8.21% in After-Hours Trading as Investors Take Profits Post-Surge","media":"Stock Track","content":"<p>Capricor Therapeutics (CAPR) saw its shares drop 8.21% in after-hours trading on Wednesday, following a dramatic intraday surge fueled by positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.</p><p>The stock had skyrocketed earlier in the day, with gains of up to 399%, after the company announced that its HOPE-3 study met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients. The after-hours decline is attributed to profit-taking by investors who capitalized on the day's substantial gains, a common occurrence following such sharp rallies.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Capricor Therapeutics Plunges 8.21% in After-Hours Trading as Investors Take Profits Post-Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Capricor Therapeutics Plunges 8.21% in After-Hours Trading as Investors Take Profits Post-Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-12-04 09:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Capricor Therapeutics (CAPR) saw its shares drop 8.21% in after-hours trading on Wednesday, following a dramatic intraday surge fueled by positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.</p><p>The stock had skyrocketed earlier in the day, with gains of up to 399%, after the company announced that its HOPE-3 study met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients. The after-hours decline is attributed to profit-taking by investors who capitalized on the day's substantial gains, a common occurrence following such sharp rallies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAPR","symbol_name":"Capricor Therapeutics Inc","start_time":0,"source_url":"","article_id":"1198590499","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198590499","pubTimestamp":1764810166,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Capricor Therapeutics (CAPR) saw its shares drop 8.21% in after-hours trading on Wednesday, following a dramatic intraday surge fueled by positive Phase 3 trial results for its Duchenne muscular...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAPR":"Capricor Therapeutics Inc"},"translate_title":"个股追踪|Capricor Therapeutics盘后暴跌8.21%投资者大涨后获利了结","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAPR":1},"content_text":"Capricor Therapeutics (CAPR) saw its shares drop 8.21% in after-hours trading on Wednesday, following a dramatic intraday surge fueled by positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.The stock had skyrocketed earlier in the day, with gains of up to 399%, after the company announced that its HOPE-3 study met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients. The after-hours decline is attributed to profit-taking by investors who capitalized on the day's substantial gains, a common occurrence following such sharp rallies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}